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Ipilimumab and Nivolumab in Rare Tumors S1609:  Neuroendocrine—
Response
Sandip P. Patel, Megan Othus, Young Kwang Chae, and Razelle Kurzrock 
As Sonbol and Halfdanarson kindly point out, the lack of central pathology 
review with utilization of local pathology reports necessitated use of the 
2010 WHO criteria for the neuroendocrine cohort in the S1609 DART study. 
We agree that central pathology review for these rare tumors would be best. 
In addition, MSI-status was not required, but will be tested on archival 
specimens as part of our translational objectives and is a focus of the 
dedicated high-grade neuroendocrine cohort currently underway within 
S1609.
